Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium
- 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated